Medical Management of Inflammatory Bowel Disease in the Elderly DOI
Farhad Peerani

Canadian IBD Today, Год журнала: 2024, Номер unknown

Опубликована: Сен. 11, 2024

The optimal management of inflammatory bowel disease (IBD) can be challenging at the best times; however, this notion becomes more salient when treating niche population elderly IBD. prevalence IBD in Canadians has almost doubled a span 5 years, increasing from 1/160 2018 to 1/88 2023. While majority patients are diagnosed between 20-40 years age, 10-15% >60 age. Elderly-onset ulcerative colitis (UC) commonly have left-sided with less extension whereas elderly-onset Crohn’s (CD) typically exhibit an colonic phenotype. Although demonstrate aggressive natural history overall, they similar risk surgery compared their adult-onset counterparts being treated non-advanced therapies. A lack physician knowledge and comfort level likely contribute maintained inappropriately on long-term steroids and/or 5-aminosalicylates. existing literature often fails differentiate aging pediatric or patients; therefore, article will discuss both groups together. Nevertheless, it is important note that these two different underlying pathophysiological mechanisms driving respective diseases which implications for therapeutic decisions. Unfortunately, evidence help guide decision-making derived retrospective analyses real-world data health administrative datasets, as well post-hoc randomized controlled trials (RCTs). Drug efficacy aside, nuanced care patient involves appreciation frailty comorbidity contextualize risks immunosuppressive therapy. Not only safety therapies contingent upon intrinsic properties drug, but addition, drug needs considered respect effectiveness controlling activity achieving corticosteroid-free remission.

Язык: Английский

The IBD Clinic of Tomorrow: Holistic, Patient-Centric, and Value-based Care DOI
Benjamin Click, Raymond K. Cross, Miguel Regueiro

и другие.

Clinical Gastroenterology and Hepatology, Год журнала: 2024, Номер 23(3), С. 419 - 427.e3

Опубликована: Июль 25, 2024

Язык: Английский

Процитировано

4
Concomitant Use of Etrasimod With Opioids or Antidepressants in Patients With Ulcerative Colitis—A Safety Analysis DOI Creative Commons
Anita Afzali, Miguel Regueiro, Andrés Yarur

и другие.

United European Gastroenterology Journal, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

ABSTRACT Background Etrasimod is an oral, once‐daily (q.d.), selective sphingosine 1‐phosphate (S1P) 1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike S1P ozanimod, etrasimod does not have a molecular structure inhibit monoamine oxidase (MAO). Coadministration drugs that MAO with opioids and antidepressants may increase risk adverse events (AEs). Aims This post hoc analysis evaluated incidence AEs potentially related serotonin syndrome in patients taking concomitant or Phase 3 ELEVATE UC 52 12 trials. Methods Safety data pooled from both trials were analysed subgroups receiving 2 mg q.d. (up weeks exposure) with/without antidepressants. We report proportions who had ≥ 1 concurrent AE associated syndrome, including hypertension‐related events. Results Among 527 etrasimod, 77 (14.6%) 35 (6.6%) antidepressants, respectively. The AEs, was low (≤ 8.6%) generally comparable all subgroups. No reported serious led discontinuation among these medications. Conclusions without further supports likelihood clinically relevant drug–drug interactions between medications commonly prescribed UC, such as ( ClinicalTrials.gov : NCT03945188; NCT03996369).

Язык: Английский

Процитировано

0
Quality of prescribing and health-related quality of life in older adults: a narrative review with a special focus on patients with atrial fibrillation and multimorbidity DOI Creative Commons
Cheïma Amrouch, Deirdre A. Lane, Amaia Calderón‐Larrañaga

и другие.

European Geriatric Medicine, Год журнала: 2025, Номер unknown

Опубликована: Март 9, 2025

Abstract Purpose To summarise the association between potentially inappropriate prescribing (PIP) and health-related quality of life (HRQOL) in older adults, with a special focus on those atrial fibrillation (AF) multimorbidity, while exploring potential interventions to improve their impact HRQOL. Methods A comprehensive search strategy was conducted MEDLINE using PubMed interface August 16th, 2024, focusing key terms related “potentially prescribing” “quality life”. Additionally, reference lists included studies were screened. Only utilising validated assessment tools for HRQOL or measuring global self-perceived health status considered. Studies involving populations an average age ≥ 65 years included. Results Of 1810 articles screened, 35 The findings indicate that prescribing, independent polypharmacy, may negatively influence review identified range aimed at improving among including pharmacist-driven, general practitioner-driven, multidisciplinary approaches. Interventions assessed distinct population groups specifically residential care homes. While some demonstrated improvements quality, overall evidence regarding remains limited. Conclusion relationship underexplored adults AF despite high prevalence PIP. Effective pharmacotherapy should be coupled patients' clinical functional parameters, considering Adopting multidisciplinary, integrated, patient-centred approach is essential sustainable appropriate practices enhance

Язык: Английский

Процитировано

0
Global burden of inflammatory bowel disease in the elderly: trends from 1990 to 2021 and projections to 2051 DOI Creative Commons
Ying Liu, Li Ju,

Guangxia Yang

и другие.

Frontiers in Aging, Год журнала: 2024, Номер 5

Опубликована: Окт. 24, 2024

This study aims to analyze the historical trends of inflammatory bowel disease (IBD) burden in elderly from 1990 2021 and forecast future up 2051.

Язык: Английский

Процитировано

2
Burden of inflammatory bowel disease among elderly, 1990–2019: A systematic analysis based on the global burden of disease study 2019 DOI

Luobei Chen,

Shaoyu Cheng, Beiping Zhang

и другие.

Autoimmunity Reviews, Год журнала: 2024, Номер unknown, С. 103708 - 103708

Опубликована: Ноя. 1, 2024

Язык: Английский

Процитировано

2
Severe Polypharmacy Increases Risk of Hospitalization Among Older Adults with IBD DOI
Darren Drittel, William Schreiber-Stainthorp,

Olivia Delau

и другие.

The American Journal of Gastroenterology, Год журнала: 2024, Номер unknown

Опубликована: Авг. 20, 2024

As the inflammatory bowel disease (IBD) patient population is aging, prevalence of polypharmacy rising. However, data exploring prevalence, risk factors, and clinical outcomes associated with among older adults IBD are limited. The aim study to determine (i) (≥5 medications) potentially inappropriate medication (PIM) utilization in IBD, (ii) changes medications over time, (iii) predictors polypharmacy, (iv) impact polypharmacy/PIMs on 1-year hospitalization rates.

Язык: Английский

Процитировано

0
Medical Management of Inflammatory Bowel Disease in the Elderly DOI
Farhad Peerani

Canadian IBD Today, Год журнала: 2024, Номер unknown

Опубликована: Сен. 11, 2024

The optimal management of inflammatory bowel disease (IBD) can be challenging at the best times; however, this notion becomes more salient when treating niche population elderly IBD. prevalence IBD in Canadians has almost doubled a span 5 years, increasing from 1/160 2018 to 1/88 2023. While majority patients are diagnosed between 20-40 years age, 10-15% >60 age. Elderly-onset ulcerative colitis (UC) commonly have left-sided with less extension whereas elderly-onset Crohn’s (CD) typically exhibit an colonic phenotype. Although demonstrate aggressive natural history overall, they similar risk surgery compared their adult-onset counterparts being treated non-advanced therapies. A lack physician knowledge and comfort level likely contribute maintained inappropriately on long-term steroids and/or 5-aminosalicylates. existing literature often fails differentiate aging pediatric or patients; therefore, article will discuss both groups together. Nevertheless, it is important note that these two different underlying pathophysiological mechanisms driving respective diseases which implications for therapeutic decisions. Unfortunately, evidence help guide decision-making derived retrospective analyses real-world data health administrative datasets, as well post-hoc randomized controlled trials (RCTs). Drug efficacy aside, nuanced care patient involves appreciation frailty comorbidity contextualize risks immunosuppressive therapy. Not only safety therapies contingent upon intrinsic properties drug, but addition, drug needs considered respect effectiveness controlling activity achieving corticosteroid-free remission.

Язык: Английский

Процитировано

0